Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy

Chantana Polprasert, M.D.,
Kitsada Wudhikarn, M.D.,
Ponlapat Rojnuckarin, M.D., Ph.D.

Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Received on July 1, 2021; Revised on August 19, 2021; Accepted on August 27, 2021

Introduction

Extranodal NK/T cell lymphomas (ENKTCLs) are aggressive cancers that originate from Epstein-Barr virus (EBV) infections. Defects in genes related to antigen presentation and T-cell activation, including human leukocyte antigen (HLA) and programmed cell death-ligand (PD-L) genes, were detected in approximately 30% among other genetic abnormalities. Immune surveillance systems play important roles in viral clearance, lymphomagenesis, and tumor progression. They may serve as prognostic biomarkers and potential targets for immunotherapy. The associations between these immune defects and clinical outcomes, as well as responses to immune checkpoint inhibitors, need to be explored.

Perspective

ENKTCLs are EBV-associated lymphomas with aggressive clinical behaviors. ENKTCL patients typically present with destructive necrotizing tumor masses that affect the upper aerodigestive tract, including the nose, nasopharynx, and paranasal sinuses. Some patients manifest more advanced stages in the lymph nodes, skin, liver, and bone marrow, indicating very poor outcomes. Current treatments include local radiotherapy and combination chemotherapy with L-asparaginase. Immunotherapy and targeted therapy are emerging treatments that may improve patient outcomes, especially in patients with advanced disease [1].

The incidence of ENKTCLs is higher in East Asia and Latin America than in other parts of the world. The genetic background of the HLA system and immune regulation is a possible explanation for the different frequencies among ethnic groups. Two genome-wide association studies conducted in East Asian populations revealed that HLA-DPB1 rs9277378 and rs9271588 and IL18RAP rs13015714 were reported to be strongly associated with ENKTCL susceptibility [2, 3]. Furthermore, a study from Japan reported that ENKTCL risk was also associated with HLA-A*26 and HLA-B*52, which are more prevalent in Asia [4]. These HLA types have been proposed to confer impaired EBV-infected cell eradication by the immune system [5]. The resulting EBV evasion and persistence in NK/T cells may cause neoplastic growth and subsequent ENKTCLs.

EBV infection associated with ENKTCL is classified as a type II latency program because tumor cells usually express EBV-encoded small RNA (EBER), EBV nuclear antigen 1 (EBNA1), and latent membrane protein 1 (LMP1). LMP1 is a viral oncoprotein that can promote abnormal NK/T cell proliferation and may enhance genomic instability via overexpression of activation-induced cytidine deaminase (AID) [4], leading to further oncogenic mutations.

In addition to the HLA system, PD-L1 and PD-L2 play...
an important role in immune surveillance; however, its role in lymphomagenesis remains unclear. PD-Ls bind to programmed cell death protein (PD) receptors, suppressing cytotoxic T lymphocyte functions, which is an immune escape method used by several cancer types. A high frequency of PD-L1/PD-L2 alterations has been reported among EBV-positive lymphomas, especially ENKTLs, compared to EBV-negative lymphomas (23% vs. 5%) [6]. HLA defects may lead to the dysregulation of the antigen presentation process, whereas PD-L1/PD-L2 overexpression may participate in tumor evasion from cellular immunity corresponding to disease progression. PD-L1/PD-L2 is frequently expressed in ENKTLs. Notably, patients with PD-L1/PD-L2 expression showed poorer survival compared to patients with low or undetectable PD-L1/PD-L2 expression [7]. Immune checkpoint inhibitors, such as anti-PD1 antibody, are emerging treatments that show promising efficacy for relapsed/refractory ENKTLs [8, 9]. Therefore, overexpression of PD-L1/PD-L2 is a potential target for immune checkpoint blockade therapy (Fig. 1).

Using next-generation sequencing technology, genetic alterations in ENKTLs were shown to involve various pathways, including epigenetic regulators (58%), RNA helicases (21%), Janus kinase–signal transducer and activator of transcription (JAK-STAT) (26%), other signal transductions (11%), tyrosine phosphatases (26%), tumor suppressors (11%), and immune surveillance (32%) [10-12]. In our study, whole-exome sequencing also revealed abnormalities in ENKTLs involving HLAs and related genes, which were somatic mutations and copy number variation, accounting for 32% [10]. Loss-of-function mutations in HLA-A were identified in 16% of the cases. Immunohistochemistry analysis revealed that a low HLA expression was associated with advanced stages.

In summary, defective viral antigen presentation may promote lymphomagenesis and progression. Additionally, the PD/PD-L pathway is employed by tumor cells to evade the immune system and can serve as a molecular target for therapy. Studies involving larger numbers of patients with ENKTL are required to correlate the HLA and PD/PD-L defects with clinical outcomes and clinical responses to anti-PD1 treatments.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Jeong SH. Extranodal NK/T cell lymphoma. Blood Res 2020; 55:563-71.
2. Li Z, Xia Y, Feng LN, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet
3. Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol 2020;21:306-16.

4. Kimura H. EBV in T-/NK-cell tumorigenesis. Adv Exp Med Biol 2018;1045:459-75.

5. Li Q, Cohen JI. Epstein-Barr virus and the human leukocyte antigen complex. Curr Clin Microbiol Rep 2019;6:175-81.

6. Kataoka K, Miyoshi H, Sakata S, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 2019;33:1687-99.

7. Muhamad H, Sukawai N, Assanasen T, Polprasert C, Bunworasate U, Wudhikarn K. Programmed cell death 1 and programmed cell death ligands in extranodal natural killer/T cell lymphoma: expression pattern and potential prognostic relevance. Acta Haematol 2020;143:78-88.

8. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 2017;129:2437-42.

9. Lai J, Xu P, Jiang X, Zhou S, Liu A. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer 2017;17:507.

10. Polprasert C, Takeuchi Y, Makishima H, et al. Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leuk Lymphoma 2021;62:95-103.

11. de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol 2019;12:33.

12. Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 2015;47:1061-6.